Patents by Inventor Jeffrey Allen Campbell

Jeffrey Allen Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9351964
    Abstract: Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: May 31, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Neil Almstead, Tamil Arasu, Soongyu Choi, Liangxian Cao, Jeffrey Allen Campbell, Donald Corson, Thomas W. Davis, Jason D. Graci, Zhengxian Gu, Peter Seongwoo Hwang, William Lennox, Harry H. Miao, Langdon Miller, Young-Choon Moon, Hongyan Qi, Christopher Trotta, Marla L. Weetall
  • Publication number: 20120330019
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 27, 2012
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • Publication number: 20120009142
    Abstract: In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 12, 2012
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Gary Mitchell Karp, Peter Seongwoo Hwang, James Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Christine Espiritu, Concetta Freund, Zhengxian Gu, Takashi Komatsu
  • Publication number: 20110268698
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IBES activity.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 3, 2011
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Gary M. KARP, Peter Seongwoo HWANG, James J. TAKASUGI, Hongyu REN, Richard Gerald WILDE, Anthony A. TURPOFF, Alexander AREFOLOV, Guangming CHEN, Jeffrey Allen CAMPBELL, Chunshi Li, Steven Paget, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Patent number: 8013006
    Abstract: In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: September 6, 2011
    Assignee: PTC Therapeutics, Inc.
    Inventors: Gary Mitchell Karp, Peter Seongwoo Hwang, James Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Christine Espiritu, Concetta Freund, Zhengxian Gu, Takashi Komatsu
  • Patent number: 7973069
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: July 5, 2011
    Assignee: PTC Therapeutics, Inc.
    Inventors: Gary M. Karp, Peter Seongwoo Hwang, James J. Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony A. Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Chunshi Li, Steven Paget, Nanjing Zhang, Jin Zhu, Xiaoyan Zhang
  • Patent number: 7868037
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: January 11, 2011
    Assignee: PTC Therapeutics, Inc.
    Inventors: Gary Mitchell Karp, Peter Seongwoo Hwang, James Jan Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Allan Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell
  • Publication number: 20100305100
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
    Type: Application
    Filed: July 1, 2010
    Publication date: December 2, 2010
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Gary Mitchell Karp, Peter Seongwoo Hwang, James J. Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Chunshi Li, Steven Paget, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Patent number: 7781478
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: August 24, 2010
    Assignee: PTC Therapeutics, Inc.
    Inventors: Gary M. Karp, Peter Seongwoo Hwang, James J. Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony A. Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Chunshi Li, Steven Paget, Nanjing Zhang, Jin Zhu, Xiaoyan Zhang
  • Patent number: 7772271
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: August 10, 2010
    Assignee: PTC Therapeutics, Inc.
    Inventors: Gary Mitchell Karp, Peter Seongwoo Hwang, James J. Takasugi, Hongyu Ren, Richard Gerald Wilde, Anthony Turpoff, Alexander Arefolov, Guangming Chen, Jeffrey Allen Campbell, Chunshi Li, Steven Paget, Nanjing Zhang, Xiaoyan Zhang, Jin Zhu
  • Patent number: 7741281
    Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R?, R3, R3?, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: June 22, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Jeffrey Allen Campbell, Fiona McPhee, Andrew Charles Good, Paul Michael Scola
  • Patent number: 7449479
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: November 11, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell
  • Patent number: 7410994
    Abstract: This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: wherein A is a —CH2—, —O—, —S—, or —S(O)—; and the other substituents are as defined in the specification; or individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: August 12, 2008
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, Jeffrey Allen Campbell
  • Patent number: 7309708
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: December 18, 2007
    Assignee: Birstol-Myers Squibb Company
    Inventors: Yong Tu, Paul Michael Scola, Andrew Charles Good, Jeffrey Allen Campbell
  • Patent number: 7173004
    Abstract: Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Fiona McPhee, Jeffrey Allen Campbell, Stanley D'Andrea, Zhizhen Barbara Zheng, Andrew Charles Good, David J. Carini, Barry L. Johnson, Paul Michael Scola, Kenneth M. Boy
  • Patent number: 7135462
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein A, R2, R3, R?, B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: November 14, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul Michael Scola, Jeffrey Allen Campbell, Ny Sin, Li-Qiang Sun, Xiangdong Alan Wang
  • Patent number: 7132504
    Abstract: Compounds are disclosed having the general formula: wherein R1, R2, R3, R4, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: November 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul Michael Scola, Fiona McPhee, Nicholas A Meanwell, Piyasena Hewawasam, Jeffrey Allen Campbell
  • Patent number: 7074939
    Abstract: This invention relates to compounds, which are generally anti-inflammatory and analgesic compounds, and which are represented by Formula I: wherein A is a —CH2—, —O—, —S—, or —S(O)—; and the other substituents are as defined in the specification; or individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: July 11, 2006
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, Jeffrey Allen Campbell
  • Patent number: 7041698
    Abstract: The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: May 9, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Amy Ripka, Jeffrey Allen Campbell, Andrew Charles Good, Paul Michael Scola, Ny Sin, Brian Venables
  • Patent number: 6995174
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 7, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Piyasena Hewawasam, Andrew Charles Good, Yan Chen, Jeffrey Allen Campbell